Show simple item record

dc.contributor.authorEchevarria, Juan Emilio 
dc.contributor.authorBanyard, Ashley C
dc.contributor.authorMcElhinney, Lorraine M
dc.contributor.authorFooks, Anthony R
dc.date.accessioned2020-01-29T11:44:59Z
dc.date.available2020-01-29T11:44:59Z
dc.date.issued2019-09-24
dc.identifier.citationViruses. 2019 Sep 24;11(10). pii: E892.es_ES
dc.identifier.issn1999-4915es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/8964
dc.description.abstractThe use of the rabies vaccine for post-exposure prophylaxis started as early as 1885, revealing a safe and efficient tool to prevent human rabies cases. Preventive vaccination is the basis for the control of canine-mediated rabies, which has already been eliminated from extensive parts of the world, including Europe. Plans to eliminate canine-mediated human rabies by 2030 have been agreed upon by international organisations. However, rabies vaccines are not efficacious against some divergent lyssaviruses. The presence in European indigenous bats of recently described lyssaviruses, which are not neutralised by antibody responses to existing vaccines, as well as the declaration of an imported case of an African lyssavirus, which also escapes vaccine-derived protection, leaves the European health authorities unable to provide efficacious protective vaccines to some potential situations of human exposure. All these circumstances highlight the need for a universal pan-lyssavirus rabies vaccine, able to prevent human rabies in all circumstances.es_ES
dc.description.sponsorshipFunding: A.C.B., A.R.F. and L.M.M. were partly funded by the UK Department for Environment, Food and Rural A airs (Defra), Scottish Government andWelsh Government under project grants SV3500 and SE0431. A.C.B. and A.R.F. are also partly funded by the European Union’s Horizon 2020 research and innovation programme under RABYD-VAX grant agreement No. 733176. J.E.E. is partly funded by the Spanish Ministry of Science, Innovation and Universities under project grant SAF2017-89355-P.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectbates_ES
dc.subjectlyssaviruses_ES
dc.subjectrabieses_ES
dc.subjectvaccinees_ES
dc.titleCurrent Rabies Vaccines Do Not Confer Protective Immunity against Divergent Lyssaviruses Circulating in Europees_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID31554170es_ES
dc.format.volume11es_ES
dc.format.number10es_ES
dc.format.page892es_ES
dc.identifier.doi10.3390/v11100892es_ES
dc.contributor.funderHorizon 2020es_ES
dc.contributor.funderMinisterio de Ciencia, Innovación y Universidades (España)es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1999-4915es_ES
dc.relation.publisherversionhttps://doi.org/10.3390/v11100892es_ES
dc.identifier.journalViruseses_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SV3500es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SE0431es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RABYD-VAX grant agreement No. 733176es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2017-89355-P.es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional